{"id":545330,"date":"2021-05-28T19:34:01","date_gmt":"2021-05-28T19:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545330"},"modified":"2021-05-28T19:34:01","modified_gmt":"2021-05-28T19:34:01","slug":"urea-cycle-disorders-ucd-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/urea-cycle-disorders-ucd-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_545330.html","title":{"rendered":"Urea Cycle Disorders (UCD) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Urea<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cUrea Cycle Disorders (UCD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Urea Cycle Disorders (UCD) , historical and forecasted epidemiology as well as the Urea Cycle Disorders (UCD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Urea Cycle Disorders (UCD) -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Urea Cycle Disorders (UCD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Urea Cycle Disorders (UCD) , historical and forecasted epidemiology as well as the  Urea Cycle Disorders (UCD)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    As per a study, the estimated incidence of Urea Cycle Disorders below 16 years of age at about 1 in 52,000 live births in Germany. <\/p>\n<\/li>\n

  2. \n

    A study reported that Ornithine transcarbamylase (OTC) deficiency was the most frequent condition followed by type 1 citrullinemia and argininosuccinic aciduria.<\/p>\n<\/li>\n

  3. \n

    As per the study, the overall Incidence of urea cycle disorders to be 1\/35,000, with 2\/3rds presenting initial symptoms after the newborn period. The mortality rate to be 24% in neonatal-onset cases and 11% in late-onset cases. <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Urea Cycle Disorders (UCD) market report covers a descriptive overview and comprehensive insight of the Urea Cycle Disorders (UCD) epidemiology and Urea Cycle Disorders (UCD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Urea Cycle Disorders (UCD) market report provides insights on the current and emerging therapies.<\/p>\n

    3.Urea Cycle Disorders (UCD) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Urea Cycle Disorders (UCD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Urea Cycle Disorders (UCD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/urea-cycle-disorders-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Urea Cycle Disorders (UCD): Overview<\/strong><\/p>\n

    A Urea Cycle Disorder (UCD) is a genetic disorder that results in a deficiency of some major enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the bloodstream. The urea cycle involves a series of biochemical steps in which nitrogen, a waste product of protein metabolism, is changed to a compound called urea and removed from the blood. Normally, the urea is removed from the body through the urine. In urea cycle disorders, nitrogen builds up in the blood in the form of ammonia, a highly toxic substance, resulting in hyperammonemia (elevated blood ammonia). Ammonia then reaches the brain through the blood, where it can cause irreversible brain damage, coma, and\/or death. The onset and severity of urea cycle disorders is highly variable. The severity correlates with the amount of urea cycle enzyme function.<\/p>\n

    The key players involved in the Urea Cycle Disorders (UCD) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      Ultragenyx Pharmaceutical<\/p>\n<\/li>\n

    2. \n

      Acer Therapeutics<\/p>\n<\/li>\n

    3. \n

      Aeglea BioTherapeutics<\/p>\n<\/li>\n

    4. \n

      Promethera Biosciences<\/p>\n<\/li>\n

    5. \n

      Kaleido Biosciences <\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Urea Cycle Disorders (UCD) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        DTX301 <\/p>\n<\/li>\n

      2. \n

        ACER-001 <\/p>\n<\/li>\n

      3. \n

        AEB1102 <\/p>\n<\/li>\n

      4. \n

        HepaStem <\/p>\n<\/li>\n

      5. \n

        KB195<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/urea-cycle-disorders-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Urea Cycle Disorders (UCD) Patient Share (%) Overview at a Glance<\/p>\n

        5. Urea Cycle Disorders (UCD) Market Overview at a Glance<\/p>\n

        6. Urea Cycle Disorders (UCD) Disease Background and Overview<\/p>\n

        7. Urea Cycle Disorders (UCD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Urea Cycle Disorders (UCD) <\/p>\n

        9. Urea Cycle Disorders (UCD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Urea Cycle Disorders (UCD) Emerging Therapies<\/p>\n

        12. Urea Cycle Disorders (UCD) Market Outlook<\/p>\n

        13. Country-Wise Urea Cycle Disorders (UCD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Urea Cycle Disorders (UCD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Urea Cycle Disorders (UCD)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Urea Cycle Disorders (UCD)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Urea Cycle Disorders (UCD) market. A detailed picture of the Urea Cycle Disorders (UCD) pipeline landscape is provided, which includes the disease overview and Urea Cycle Disorders (UCD) treatment guidelines.<\/p>\n

        Urea Cycle Disorders (UCD) -Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Urea Cycle Disorders (UCD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Urea Cycle Disorders (UCD){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cUrea Cycle Disorders (UCD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Urea Cycle Disorders (UCD) , historical and forecasted epidemiology as well as the Urea Cycle Disorders (UCD) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-545330","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545330"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545330\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}